ClinicalRM Awarded Contract for Regulatory, Clinical and Technical Services to Support the US Army Medical Material Development Activity (USAMMDA)
Clinical Research Management, Inc. (ClinicalRM), a full-service Contract Research Organization providing services for basic and applied research, clinical trials, and regulatory support, announced today it was awarded a USAMMDA contract. With this contract, ClinicalRM will provide regulatory support personnel and may also provide equipment, supplies, facilities, transportations, tools, and materials necessary to support USAMMDA’s mission. The contract award number is W81XWH-13-C-0003, and is effective for 5 years, including option renewals, as of November 1, 2012.
USAMMRD supports ongoing efforts to develop new drugs, vaccines, devices, and medical support equipment that enhance readiness, endures the provision of the highest quality medical care to the Department of Defense (DoD), and maximizes the survival of medical casualties on the battlefield.
“ClinicalRM is honored to continue the support of the important USAMMDA mission throughthis new contract,” said Edie Druktenis, ClinicalRM Program Manager. “Our staff is highly qualified and have proven to be a great asset to the mission over the last couple of years to move solutions forward, developing medical material to protect and sustain the warfighter.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
